{"id":"W2909334052","doi":"10.1200/jco.18.00766","title":"Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study","year":2019,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":363,"is_retracted":false,"has_abstract":true,"ca_institutions":"Jewish General Hospital","funders":"Cilag; National Cancer Institute; Pharmacyclics; Genentech; Servier; Incyte; Celgene; LAM Therapeutics; Adaptive Biotechnologies; Astex Pharmaceuticals; Regeneron Pharmaceuticals; Janssen Pharmaceuticals; Kite Pharma; Gilead Sciences; Bristol-Myers Squibb; AstraZeneca; Takeda Oncology; Amgen; Pfizer","keywords":"Medicine; Nivolumab; Cohort; Internal medicine; Refractory (planetary science); Transplantation; Surgery; Adverse effect; Oncology; Diffuse large B-cell lymphoma; Lymphoma; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001720039,0.001272554,0.00189482,0.0002715057,0.0003455242,0.0008715633,0.0006253929,0.0009529651,0.0012077],"category_scores_gemma":[0.0007521248,0.0004297468,0.001225104,0.000232664,0.0008396675,0.0006177138,0.000268906,0.002063347,0.0004446204],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008325676,"about_ca_system_score_gemma":0.001083592,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005128031,"about_ca_topic_score_gemma":0.001239614,"domain_scores_codex":[0.9995884,0.0001995461,0.0000237967,0.00007240375,0.00004172017,0.00007413037],"domain_scores_gemma":[0.9993789,0.00009864384,0.0001232808,0.00007583285,0.00003436656,0.0002889516],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6581975,0.1196648,0.03294877,0.0008711964,0.002259837,0.0005262931,0.0006346045,0.003571221,0.06833442,0.0002116228,0.001798508,0.1109812],"study_design_scores_gemma":[0.4227894,0.5451341,0.02435985,0.00003487124,0.0004988236,0.0004284279,0.00007810367,0.001885315,0.003459199,0.0001204711,0.00118059,0.00003092955],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9983156,0.0006137139,0.0001579806,0.00006785971,0.00002768407,0.000477703,0.0001290326,0.00001957725,0.0001907641],"genre_scores_gemma":[0.9972831,0.0004848399,0.0005110282,0.0002471017,0.00006819284,0.0006161106,0.0004205749,0.000008243992,0.0003607995],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00189482,"threshold_uncertainty_score":0.009096563,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07914781576734928,"score_gpt":0.4257238446997092,"score_spread":0.3465760289323599,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}